"The pipeline is rich as a
result of the all of the research being conducted, and I see the NSCLC market
significantly expanding in the coming years with more novel targeted
therapies."
— Winston Wong, Pharm.D., president of W-Squared Group, spoke
with AIS's RADAR on Specialty
Pharmacy about the FDA's seven recent drug approvals in the
non-small cell lung cancer market basket, and what it means for patients and
providers.
No comments:
Post a Comment